NOUS-209 is an off-the-shelf therapeutic vaccine based on shared tumor neoantigens.
NOUS-209 is being administered in a clinical trial to patients with Microsatellite Instable High (MSI-H) gastric, colorectal and gastroesophageal junction cancers.
The recommended dosage is being determined in the clinical trial
Clinical Trial NCT04041310: Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors RECRUITING
- NOUS-209-01 is a multicenter, open-label, multiple cohorts, First In Humans (FIH) clinical study, designed to evaluate safety, tolerability, and immunogenicity, and to detect any preliminary evidence of anti-tumor activity of Nous-209 genetic polyvalent vaccine based on a heterologous prime/boost regimen composed of the GAd20-209-FSP used for priming and MVA-209-FSP used for boosting in patients with unresectable or metastatic Mismatch Repair Deficient (dMMR) or Microsatellite Instability High (MSI-H) colorectal cancer (CRC), gastric, gastroesophageal junction (G-E junction) and endometrial tumors in sporadic or hereditary forms of the diseases.